Dogwood Therapeutics DWTX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's accrued expenses?
- Dogwood Therapeutics (DWTX) reported accrued expenses of $2.35M in Q1 2026.
- How has Dogwood Therapeutics's accrued expenses changed year-over-year?
- Dogwood Therapeutics's accrued expenses increased by 70.8% year-over-year, from $1.38M to $2.35M.
- What is the long-term trend for Dogwood Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Dogwood Therapeutics's accrued expenses has grown at a 23.4% compound annual growth rate (CAGR), from $784.1K to $2.24M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.